Panion Animal Health AB sets its sights on the USA

After raising new capital, veterinary medicine company Panion Animal Health AB is now ready to ramp
up development of its treatment method for canine epilepsy. At the same time, discussions are under
way for a licensing deal that could give Panion access to a new major market.

"There is a very good likelihood that Panion will have two products in the pipeline within two to four years," says Lars Thunberg, chairman of Panion Animal Health AB. Panion has signed an LOI with a company for a gene therapeutic treatment of equine osteoarthritis. The DD process has started and is expected to be completed during Q4 (2017).

In May Panion raised 7.4 million kronor via a new share issue. The company has since been listed on Aktietorget. The capital infusion will enable Panion to proceed with a pilot study in which the effect of the company's treatment method in dogs will be investigated. Panion is developing a gene therapy treatment of canine epilepsy. That the planned study will be conducted at a university hospital in North Carolina, USA, is no accident, according to Lars Thunberg.

The USA is the home market
"We've always had our sights set on the US market, and that's no exaggeration. When it comes to veterinary medicine, it is the world's largest, not least where dogs are concerned," he says. The pilot study is expected to reach completion by the end of this year, after which a further study will be conducted. Then, appropriate doses will be determined, both with respect to the efficacy of the treatment and in terms of side effects. This study, which is expected to be completed midway through next year, will be conducted under the supervision of the FDA. Subsequently, concluding studies will be done. The treatment may be launched sometime around 2020. By then, Panion may very well have other projects in the offing.

That Panion is moving into the US market is evidenced by the fact that the company has opened an office in New York, with local specialists who have indepth knowledge of the market. The office, at 958 Lexington Avenue, opened in June. Carlos Velez (Director Business Development), Dave Peterick (FDA expert consultant) and Beth Ohman (US-based clinical trial monitor) will man the representation office.

The above/mentioned are employed on a consultancy basis to plan and develop coming trials in the USA. With over fifty years of combined experience of handling tasks of the kind Panion is now facing, these individuals have been carefully selected for the roles described above.

Panion will be doing a road show in the USA in late July, when the company will be presented for several investment banks. The American market for veterinary gene therapy has enormous potential is is much bigger than the European market. The market is driven by new products that are continuously reaching animal owners.

14 JULI 2017

For further information, please contact:
Anja E. H. Holm, VD | + 45-22 94 66 00

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication at 08.30 a.m.on 14 July 2017.

In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGene's shareholders with the aim of listing the company. The company, which has been renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a treatment for canine epilepsy. Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

Nerladdningsbara filer

2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 663 (-697).
  • Earnings per share: SEK -0,07 (-0,05).
  • Liquidity at the end of the period: kSEK 4 961 (2 708).

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.

CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").

Kommentar avseende revisorns anmärkning i publicerad årsredovisning för 2018

Angående revisorns anmärkning i årsredovisning 2018

Kallelse till årstämma i Panion Animal Health AB

Aktieägarna i Panion Animal Health AB (publ), 559018-4171, kallas härmed till årsstämma tisdagen den 23 april 2019 kl. 14.00 på Mazars SET Revisionsbyrå ABs kontor, Scheelevägen 17, i Lund.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90